Schroy P, Winawer S, Friedman E
Gastroenterology Service, Memorial Sloan-Kettering Cancer Center, New York, NY 10021.
Cancer Lett. 1989 Nov 15;48(1):53-8. doi: 10.1016/0304-3835(89)90202-4.
The heterogeneity of tumor responses to maturation agents was studied using the multi-potential, non-cloned human colon carcinoma cell line HT29. Short-term treatment (5 cell doublings) with the differentiation agent hexamethylene bisacetamide (HMBA) induced a sharp decrease in tumorigenicity in vivo and loss of a cell surface malignancy marker. However, prolonged treatment (22 cell doublings) with the agent lead to loss of the HMBA-sensitive subpopulation from the mass culture, and enrichment of a tumorigenic, HMBA-resistant subpopulation.
利用多能性、未克隆的人结肠癌细胞系HT29研究了肿瘤对成熟剂反应的异质性。用分化剂六甲双乙酰胺（HMBA）进行短期处理（5个细胞倍增）可导致体内致瘤性急剧下降以及细胞表面恶性标志物的丧失。然而，用该试剂进行长时间处理（22个细胞倍增）会导致大量培养物中HMBA敏感亚群的丧失，以及致瘤性、HMBA抗性亚群的富集。
